FROM CLINIC TO CURE: Integrating Safer Novel Alternatives into Comorbidity-Centred Cessation Care
 
 
 

Welcome to Redefining Smoking Cessation!
 
 
 
 
Dear Healthcare Practitioner,

Smoking cessation counselling has traditionally operated in a silo — addressed in isolation, seldom calibrated to the specific disease burden each patient carries. Yet the evidence is now unambiguous: India's tobacco users are disproportionately patients already managing cardiovascular disease, diabetes, tuberculosis, or chronic respiratory illness. For these patients, quitting is not merely a lifestyle preference — it is a disease-modifying intervention. And for clinicians managing these comorbidities, integrating Safer Novel Alternatives (SNAs) into disease-specific cessation pathways is no longer optional. It is a clinical imperative.
India carries over 253 million tobacco users (Global Action to End Smoking, 2022), and the smoking quit ratio stands at only 21.1% nationally — with fewer than 15% of quit attempts using any pharmacotherapy or structured support (GATS-2 India; Scientific Reports, 2025). With tobacco contributing to cardiovascular disease, TB amplification, glycaemic dysregulation, and COPD progression, HCPs across specialties sit at the most consequential intervention point in the cessation pathway.
 
 
 
 
 
THE COMORBIDITY-CESSATION NEXUS: WHY DISEASE CONTEXT TRANSFORMS THE QUIT EQUATION
 
The case for comorbidity-integrated cessation is not theoretical — it is quantified and urgent. Consider the clinical landscape your patients inhabit:
● Cardiovascular Disease: Smoking is responsible for approximately 20% of all cardiovascular deaths globally.
● Tuberculosis: Smoking prevalence among TB patients in India is approximately double that of the general population.
● Diabetes & Metabolic Disease: Smoking significantly impairs insulin sensitivity and glycaemic control.
● Mental Health: Smoking prevalence is two to three times higher in patients with psychiatric conditions.
 
 
 
 
SNA EVIDENCE IN COMORBID POPULATIONS: WHAT THE DATA NOW SHOWS

 

 
 

The 2025 Cochrane Living Systematic Review — the most comprehensive evidence synthesis to date, covering 104 studies and 30,366 participants — now provides high-certainty evidence that nicotine e-cigarettes outperform NRT for smoking cessation, with a Risk Ratio of 1.55 (95% CI: 1.28–1.88) (Cochrane Database Syst Rev, 2025).
 
 
 
 
 
THE HCP ACTION GAP — AND HOW TO CLOSE IT
 
For Indian HCPs across specialties, three targeted actions can meaningfully shift outcomes:
● Screen at every comorbidity consultation: Tobacco status should be documented alongside BP, glucose, and BMI as a routine vital sign — especially in diabetes, cardiac, and TB clinics.
● Deploy personalised SNA protocols: Tailor pharmacotherapy selection to the patient's comorbidity profile — varenicline for CV and psychiatric patients; NRT for those where tolerability is a concern; digital tools as adjuncts across all groups.
● Institutionalise the follow-up loop: Cessation support without arranged follow-up is only 50% complete. Scheduling the next cessation check-in at the point of advice — not as a separate referral — is the single highest-yield structural change a clinic can make.
 
 
 
 
 

 
 

CLINICAL TAKEAWAYS FOR YOUR PRACTICE
The evidence convergence of 2025 points to one operational conclusion: cessation is a disease management strategy, not an addendum. For HCPs:
● Treat tobacco status as a modifiable risk factor in every comorbidity consultation — document, advise, and act within the same clinical encounter
● Use the 5As-AAC framework actively — particularly 'Arrange,' which remains the most underutilised yet highest-impact step
● Consider SNAs and pharmacotherapy as first-line adjuncts for patients with cardiovascular disease, TB, diabetes, and psychiatric conditions — where unaided quit rates are demonstrably lower
● Integrate digital support tools as force-multipliers — the 59.2% vs. 38.7% gap between multimodal and pharmacotherapy-only approaches represents real patients successfully quitting
● Leverage disease diagnosis moments as cessation triggers — the 'teachable moment' of a new cardiac diagnosis or TB initiation is clinically the most powerful quit motivator available
 
 
 
 
 
You are receiving this email because you have subscribed to receive updates from us.
Should you wish to cancel your subscription, please click here to unsubscribe.